Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Price

TNXPStock

$13.59−55.89%52W

Market Cap$233.08M

P/E—

PEG Ratio—

Div yield—

Beta1.79

TNXP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-16.83%

Price vs S&P 500 (4W)25.88%

VGM Score67.83

Book Value / Share (Quarterly)$15.99

P/TBV (Annual)0.82x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-9.20

Price vs S&P 500 (YTD)-25.82%

Gross Margin (TTM)58.56%

Net Profit Margin (TTM)-839.52%

EPS (TTM)$-14.34

10-Day Avg Trading Volume0.48M

EPS Excl Extra (TTM)$-14.34

EPS (Annual)$-14.57

ROI (Annual)-50.59%

Gross Margin (Annual)49.34%

Cash / Share (Quarterly)$13.06

Revenue Growth QoQ (YoY)183.16%

ROA (Last FY)-44.75%

Revenue Growth TTM (YoY)74.84%

EBITD / Share (TTM)$-14.28

ROE (5Y Avg)-69.94%

Operating Margin (TTM)-861.16%

Cash Flow / Share (Annual)$-8.07

P/B Ratio0.94x

P/B Ratio (Quarterly)0.86x

Net Income / Employee (Annual)$-873,400

EV / Revenue (TTM)1.65x

Net Interest Coverage (TTM)-2.39x

ROA (TTM)-60.47%

EPS Incl Extra (Annual)$-14.57

Current Ratio (Annual)7.42x

Quick Ratio (Quarterly)6.59x

3-Month Avg Trading Volume0.50M

52-Week Price Return-55.89%

Revenue / Employee (TTM)$123,600

Tangible BV / Share (Quarterly)$15.98

P/S Ratio (Annual)16.36x

Asset Turnover (Annual)0.05x

52-Week High$33.22

EPS Excl Extra (Annual)$-14.57

CapEx CAGR (5Y)-17.01%

Tangible BV CAGR (5Y)91.96%

26-Week Price Return-4.90%

Quick Ratio (Annual)6.99x

13-Week Price Return7.52%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.99x

Enterprise Value$28.92M

Asset Turnover (TTM)0.07x

Book Value / Share Growth (5Y)-26.22%

Revenue / Employee (Annual)$92,300

Pretax Margin (Annual)-946.22%

Cash / Share (Annual)$16.24

3-Month Return Std Dev67.98%

Net Income / Employee (TTM)$-1,037,900

ROE (Last FY)-50.59%

Net Interest Coverage (Annual)-421.14x

EPS Basic Excl Extra (Annual)$-14.57

Receivables Turnover (TTM)2.89x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-14.34

ROI (TTM)-67.65%

P/S Ratio (TTM)12.21x

Revenue / Share (Annual)$1.54

Tangible BV / Share (Annual)$19.16

Price vs S&P 500 (52W)-74.45%

Year-to-Date Return-13.00%

5-Day Price Return9.16%

EPS Normalized (Annual)$-14.57

ROA (5Y Avg)-57.45%

Net Profit Margin (Annual)-946.22%

Month-to-Date Return35.76%

Cash Flow / Share (TTM)$-10.41

EBITD / Share (Annual)$-14.79

Operating Margin (Annual)-975.01%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-67.27%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-14.34

P/TBV (Quarterly)0.86x

P/B Ratio (Annual)0.81x

Inventory Turnover (TTM)1.24x

Pretax Margin (TTM)-839.52%

Book Value / Share (Annual)$19.17

Price vs S&P 500 (13W)5.56%

Beta1.79x

Revenue / Share (TTM)$1.28

ROE (TTM)-67.65%

52-Week Low$9.40

vGradeB

gGradeA

mGradeC

vgmGradeB

TNXP Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 10, 2026	-$2.62	-$2.47	+5.58%(+$0.15)
Q1 2026	May 11, 2026	-$2.54	-$2.93	-15.35%(-$0.39)
Q4 2025	Mar 12, 2026	-$2.94	-$3.98	-35.44%(-$1.04)
Q3 2025	Nov 10, 2025	-$3.58	-$3.59	-0.14%(-$0.01)
Q2 2025	Aug 11, 2025	-$1.88	-$4.00	-112.76%(-$2.12)

TNXP Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.13

4.11

4.20

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
TNXPTonix Pharmaceuticals Holding Corp.	B	A	C	$13.59
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals is a commercial-stage biotech company developing treatments for CNS disorders and immunological conditions. Its approved product TONMYA treats fibromyalgia, while marketed migraine medications Zembrace SymTouch and Tosymra provide current revenue. The company is expanding TONMYA into depression and acute stress disorder through clinical trials and advancing a pipeline including TNX-4800 for Lyme disease prevention and TNX-1500 for transplant rejection prevention.